Brokerages Set Alnylam Pharmaceuticals, Inc. (ALNY) Price Target at $138.07

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has received an average rating of “Buy” from the twenty analysts that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and fourteen have assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $139.00.

Several equities research analysts have recently commented on ALNY shares. ValuEngine lowered Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, January 2nd. Zacks Investment Research lowered Alnylam Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, October 8th. BidaskClub lowered Alnylam Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, October 24th. Leerink Swann started coverage on Alnylam Pharmaceuticals in a research note on Tuesday, November 27th. They issued a “market perform” rating and a $63.00 price objective for the company. Finally, BMO Capital Markets restated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, October 18th.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC boosted its holdings in shares of Alnylam Pharmaceuticals by 768.5% during the 3rd quarter. Tower Research Capital LLC TRC now owns 1,294 shares of the biopharmaceutical company’s stock valued at $113,000 after purchasing an additional 1,145 shares during the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC bought a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at about $137,000. Opera Trading Capital bought a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at about $137,000. Harel Insurance Investments & Financial Services Ltd. boosted its holdings in shares of Alnylam Pharmaceuticals by 600.9% during the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,278 shares of the biopharmaceutical company’s stock valued at $200,000 after purchasing an additional 1,953 shares during the last quarter. Finally, First Republic Investment Management Inc. bought a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at about $230,000. 88.42% of the stock is owned by institutional investors and hedge funds.

ALNY traded up $2.44 during mid-day trading on Tuesday, reaching $83.12. 1,062,958 shares of the company traded hands, compared to its average volume of 902,956. The firm has a market cap of $8.41 billion, a PE ratio of -15.34 and a beta of 2.32. The company has a current ratio of 11.05, a quick ratio of 10.96 and a debt-to-equity ratio of 0.02. Alnylam Pharmaceuticals has a 52-week low of $60.27 and a 52-week high of $153.99.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported ($2.43) EPS for the quarter, missing the consensus estimate of ($2.02) by ($0.41). The company had revenue of $2.07 million during the quarter, compared to analysts’ expectations of $22.66 million. Alnylam Pharmaceuticals had a negative return on equity of 43.07% and a negative net margin of 754.13%. The company’s revenue for the quarter was down 87.9% on a year-over-year basis. During the same quarter last year, the company earned ($1.34) earnings per share. As a group, research analysts forecast that Alnylam Pharmaceuticals will post -7.79 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.

Featured Article: How is inflation measured?

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply